CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Releases Q1 2021 Report, Business Updates

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients, reported its first-quarter 2021 financial and operating results. Highlights from the report include the appointment of Dr. Mathias Schuetz to vice president and Dr. Trish Choudhary to vice president, research & development; the closing of its public offering, comprised of … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Releases Q1 2021 Report, Business Updates”

CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Announces Completion of Groundbreaking Study on CBG Use on Skin

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has completed a series of studies evaluating the safety and anti-inflammatory, anti-aging, and antimicrobial properties of its cannabigerol (“CBG”) when used on skin. The studies were conducted in collaboration with Signum Biosciences Inc., … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Announces Completion of Groundbreaking Study on CBG Use on Skin”

CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Completes 1st Commercial Scale Fermentation Run of CBG

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF) today announced its completion of the first commercial scale fermentation run of its first cannabinoid for market, cannabigerol (“CBG”). “We are very pleased with the yield and quality of our first commercial scale fermentation run of CBG,” said Trevor Peters, Willow’s president and chief executive officer. “I think it … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Completes 1st Commercial Scale Fermentation Run of CBG”

CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Releases Q4 and FY 2020 Financial, Operational Report

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has announced its fourth-quarter and full-year numbers for the period ended Dec. 31, 2020. In the report, Willow noted that it had filed a short form base shelf prospectus that allowed the company … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Releases Q4 and FY 2020 Financial, Operational Report”

CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Secures $28.75M in Bought Deal Offering

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF) has closed its previously announced upsized bought deal offering of 17,424,800 common shares of the company, each at a price of $1.65, including 2,272,800 common shares issued per the full exercise of the over-allotment option. Willow Biosciences secured aggregate gross proceeds of approximately $28.75 million in the offering, which … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Secures $28.75M in Bought Deal Offering”

CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Releases Update on THC, Plans for Canadian Market Launch

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has made advancements on its work on a proprietary yeast strain for the production of Tetrahydrocannabinol (“THC”); the company also announced plans to commercially launch the product in the highly regulated, legal Canadian … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Releases Update on THC, Plans for Canadian Market Launch”

CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Announces Progress in Commercialization Plan with Initial Product Expected in Q1 2021

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF) has contracted with a leading manufacturer to produce its first cannabinoid, cannabigerol (“CBG”); the first production run is slated for early 2021 and will result in commercial quantities of Willow’s ultra-pure CBG. The product will be manufactured in Europe. In addition, Willow announced plans to run a second 500-litre … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Announces Progress in Commercialization Plan with Initial Product Expected in Q1 2021”

CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Announces Q3 2020 Results, Operational Update

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a Vancouver, Canada-based company focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, has released its financial and operating results for the three and nine months ended September 30, 2020. According to the update, Willow Biosciences reported significant advancement in its operations and strong liquidity. The update reads, “The third … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Announces Q3 2020 Results, Operational Update”

CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Secures $11.5M in Upsized Public Offering

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a Vancouver, Canada-based company focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, has closed its previously announced upsized public offering of 17,692,307 units of the company, each at a price of $0.65, including 2,307,692 units issued pursuant to the full exercise of the over-allotment option. The company secured aggregate … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Secures $11.5M in Upsized Public Offering”

CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) to Support Research on Therapeutic Potential of Non-Psychoactive Cannabinoids

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a Vancouver, Canada-based company focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, today announced its partnership with researchers at the University of Lethbridge and the University of Calgary. According to the update, the collaboration is designed to study the therapeutic potential of non-psychoactive cannabinoids in relation to intestinal inflammation, … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) to Support Research on Therapeutic Potential of Non-Psychoactive Cannabinoids”

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977